<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001789</url>
  </required_header>
  <id_info>
    <org_study_id>8185</org_study_id>
    <nct_id>NCT05001789</nct_id>
  </id_info>
  <brief_title>Cognitive Functioning in Opioid Use Disorder</brief_title>
  <official_title>Cognitive Functioning in Opioid Use Disorder: Examining the Impacts of Computerized Working Memory Training and Non-Fatal Opioid Overdose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This outpatient study is designed to examine the potential relationship between non-fatal&#xD;
      opioid overdose and cognitive functioning. This study will also examine the impact of&#xD;
      computerized working memory training on relevant outcomes (cognition, psychosocial&#xD;
      functioning, quality of life, drug use). The training component of the study lasts 1 month,&#xD;
      with follow up visits and 1-month and 3-months post training.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This outpatient study is designed to examine the potential relationship between non-fatal&#xD;
      opioid overdose (i.e. overdose that does not result in death), cognitive functioning, and the&#xD;
      impact of computerized working memory training on relevant outcomes (cognition, psychosocial&#xD;
      functioning, quality of life). Participants (n=30) with a history of at least one prior&#xD;
      opioid OD, who are enrolled in buprenorphine treatment, will be randomized to 20 sessions of&#xD;
      an active (n=15) or sham (n=15) working memory training. Patients will complete measures of&#xD;
      cognitive functioning during screening, post-training, and at 1-month and 3-month follow up.&#xD;
      Participants will also complete the measures of decision making, psychosocial functioning and&#xD;
      drug use at baseline, post-training, and follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participants and research staff will be blinded to participant's training condition (active vs. sham)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NIH Toolbox Cognition Battery</measure>
    <time_frame>Post-Training (1-month from baseline)</time_frame>
    <description>A brief computerized test of key neuropsychological functions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NIH Toolbox Cognition Battery</measure>
    <time_frame>1-month Follow up</time_frame>
    <description>A brief computerized test of key neuropsychological functions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NIH Toolbox Cognition Battery</measure>
    <time_frame>3-month Follow up</time_frame>
    <description>A brief computerized test of key neuropsychological functions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychosocial Functioning (Brief Inventory of Psychosocial Functioning B-IPF)</measure>
    <time_frame>Post-training (1 month from baseline)</time_frame>
    <description>B-IPF: scores range from 0 to 49 with higher scores indicating greater difficulties with psychosocial functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychosocial Functioning (Brief Inventory of Psychosocial Functioning B-IPF)</measure>
    <time_frame>1-month follow up</time_frame>
    <description>B-IPF: scores range from 0 to 49 with higher scores indicating greater difficulties with psychosocial functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychosocial Functioning (Brief Inventory of Psychosocial Functioning B-IPF)</measure>
    <time_frame>3-month follow up</time_frame>
    <description>B-IPF: scores range from 0 to 49 with higher scores indicating greater difficulties with psychosocial functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Illicit Substance Use: Timeline Follow Back (TLFB)</measure>
    <time_frame>Post-training (1-month from baseline)</time_frame>
    <description>TLFB: measures substance use in the past 1-week period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Illicit Substance Use: Timeline Follow Back (TLFB)</measure>
    <time_frame>1-month follow up</time_frame>
    <description>TLFB: measures substance use in the past 1-week period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Illicit Substance Use: Timeline Follow Back (TLFB)</measure>
    <time_frame>3-month follow up</time_frame>
    <description>TLFB: measures substance use in the past 1-week period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Scale (QOLS)</measure>
    <time_frame>Post-training (1 month from baseline)</time_frame>
    <description>QOLS: scores range from 16 to 112 with higher scores indicating greater quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Scale (QOLS)</measure>
    <time_frame>1-month follow up</time_frame>
    <description>QOLS: scores range from 16 to 112 with higher scores indicating greater quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Scale (QOLS)</measure>
    <time_frame>3-month follow up</time_frame>
    <description>QOLS: scores range from 16 to 112 with higher scores indicating greater quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impulsive decision making (Delay Discounting Task)</measure>
    <time_frame>Post-training (1 month from baseline)</time_frame>
    <description>Delay Discounting Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impulsive decision making (Delay Discounting Task)</measure>
    <time_frame>1-month follow up</time_frame>
    <description>Delay Discounting Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impulsive decision making (Delay Discounting Task)</measure>
    <time_frame>3-month follow up</time_frame>
    <description>Delay Discounting Task</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Opioid Use</condition>
  <condition>Cognitive Change</condition>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Working memory training with task-difficulty increasing across sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Working memory training with task-difficulty remaining constant across sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CogMed</intervention_name>
    <description>20 sessions of Cogmed working memory training</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets DSM-5 criteria for moderate-severe Opioid Use Disorder (OUD) in the past 6&#xD;
             months&#xD;
&#xD;
          -  Enrolled in a suboxone (buprenorphine/naloxone) program; willing to provide consent&#xD;
             for research team to contact treatment provider&#xD;
&#xD;
          -  History of at least 1 prior opioid overdose&#xD;
&#xD;
          -  Recent history of illicit opioid use&#xD;
&#xD;
          -  In good physical health&#xD;
&#xD;
          -  Access to a smartphone, tablet, or computer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of a co-occurring, untreated psychiatric condition that would make&#xD;
             participation risky or difficulty&#xD;
&#xD;
          -  Lack of access to a home computer, smartphone, or tablet&#xD;
&#xD;
          -  Unable to speak, read and/or communicate in English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NY State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel R Luba, PhD</last_name>
      <phone>646-774-6495</phone>
      <email>Rachel.Luba@nyspi.columbia.edu</email>
    </contact>
    <contact_backup>
      <phone>646-774-6243</phone>
    </contact_backup>
    <investigator>
      <last_name>Luba R Rachel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Comer Sandra, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Sandra D. Comer</investigator_full_name>
    <investigator_title>Professor of Neurobiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 6, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT05001789/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

